A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer
Pelley, Robert ; Ganapathi, Ram ; Wood, Laura ; Rybicki, Lisa ; McLain, Denise ; Budd, G. Thomas ; Peereboom, David ; Olencki, Thomas ; Bukowski, Ronald M.
Springer
Published 2000
Springer
Published 2000
| ISSN: |
1432-0843
|
|---|---|
| Keywords: |
Key words Colorectal cancer ; Metastatic ; Pyrazoloacridine ; Phase II trial
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract Purpose: To perform a phase II trial of pyrazoloacridine (PZA), a novel DNA intercalator, in patients with metastatic colorectal carcinoma and no previous therapy. Methods: PZA was administered at a dose of 750 mg/m2 intravenously over 3 h every 21 days. Pharmacokinetic studies to determine PZA plasma concentrations were performed. Results: No responses were seen in 14 response-evaluable patients. Patients received a median of two cycles of PZA (range 1–6). Toxicity included neutropenia and neurologic side-effects, which were ≥ grade III in 73% and 14%, respectively. High plasma concentrations of PZA (Cmax) correlated with low neutrophil counts (P=0.04). Conclusions: PZA is inactive at this dose and schedule in colorectal cancer, and produces moderately severe toxicity.
|
| Type of Medium: |
Electronic Resource
|
| URL: |